SBIR/STTR Research Award
Tools for Improved Translation of Novel Inhalable Therapeutics
Award amount
$274,222Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- POWERSCOPE, INC
- Proposal award date
- 2019-05-15
- Contract end date
- 2020-11-30
- UEI
- Not reported
- Solicitation number
- PA18-574
- Topic code
- NHLBI
Research abstract
Project Summary: With delineation of the pathogenesis of lung diseases, significant advances are being
achieved in the pharmaceutical development of therapeutic interventions. New putative drugs are continually
being identified; however, their initial availability is often extremely limited, particularly for biologically-based,
macromolecule agents (e.g. proteins, genes, RNA, and antibodies). Translation of these agents is particularly
challenging if the delivery mode is inhalation. Existing rodent exposure systems are unsuitable for these
compounds, as typically more than 99% of the drug is lost. While it is possible to administer a small volume of
solution of the agent to rodent models with an endotracheal needle, this requires anesthesia and results in
poor distribution in the lung. This project addresses the critical need of efficient inhalation delivery--first in
rodents and then in larger animals and human patients. An efficient rodent inhalation exposure system is
needed not only for testing putative therapies but also infectious agents, new vaccines and engineered
nanomaterials.
Our proposed approach is non-invasive and will not require anesthesia and thus is amenable for trauma-free,
daily dosing. Aerosols will be generated with a small volume of liquid (e.g. 10 micro-liters) with essentially no
liquid trapped in the device. Further, the particles will be produced close to the nares of the animal, which will
minimize the dead volume and thereby the loss of the agent. Aerosols escaping lung deposition will be
electrostatically deposited on a mass microbalance equipped for real-time readout. The benefits include: (1)
aerosol exposure will be monitored in real time allowing immediate dosing adjustments, and (2) fluctuations in
the mass deposition on the microbalance would reveal the breathing frequency and tidal volume of the animal.
The proposed device is expected to have an inhalation efficiency of about 60%.
We propose to construct a prototype exposure system utilizing “mechanical rodents” designed to simulate the
anatomy/physiology of a rodent’s respiratory system with adjustable respiratory minute volume as well as
breathing frequency for application to either a mouse or a rat. Aerosols inhaled by the mechanical rodent will
be collected on a filter to assess deposition. Further, we will validate the exposure system in-vivo with mice for
the total pulmonary deposition as well as distribution of inhaled aerosol in the pulmonary tree using
‘nanocapsules’ of macromolecular drugs encapsulated in a ligand shell enabling targeted delivery to solid
tumor cells and inflamed fibroblastic cells.
Successful completion of this work would establish the feasibility of the proposed exposure system for highly
efficient inhalation exposure. In Phase II, this device will be developed into a multiple animal exposure system
and used for safety and efficacy studies of nanocapsules in treating lung cancer and chronic obstructive
pulmonary disease.PROJECT NARRATIVE
New compounds for inhalation delivery are often tested with rodents through invasive endotracheal access
under anesthesia, as non-invasive aerosol delivery is too wasteful to be practical. We propose development of
a new highly-efficient non-invasive aerosol delivery system for rodents, with the additional benefits of real-time
monitoring and plethysmography. Through advancement of rodent inhalation exposure equipment, this project
promises to shorten the time from discovery to regulatory approval for new inhalation drugs. The advanced
exposure system would also significantly improve the outcome of preclinical studies on infectious agents,
inhalation vaccines and airborne nanomaterials.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications